Latest ENTX news and sentiment

Entera Bio (NASDAQ:ENTX) Stock Price Up 5.1% - Here's Why

Entera Bio (NASDAQ:ENTX) saw its stock price increase by 5.1% to $3.27, although trading volume was significantly lower than average. Analyst sentiment is mixed, with a consensus "Hold" rating and a target price of $9.00. The company reported a quarterly loss of $0.14 per share, missing the consensus estimate, and institutional investors collectively own 14.11% of the stock.

Entera Bio appoints Riccardo Camisasca as chief medical officer

Entera Bio Ltd. (NASDAQ:ENTX) has announced the appointment of Riccardo Paolo Camisasca, M.D., as its new Chief Medical Officer. Dr. Camisasca brings over 30 years of experience in clinical development and R&D leadership, previously serving as Global Head of Research & Development at Sumitomo Pharma Switzerland. His appointment comes as Entera Bio prepares to begin a Phase 3 trial for EB613, an oral treatment for osteoporosis.

Form 8K Entera Bio Ltd. For: 18 August By Investing.com

This article reports that Entera Bio Ltd. filed a Form 8K on August 18th. The filing is a standard SEC document used to announce significant events that shareholders should know about. No specific details about the content of the Form 8K are provided in this brief news item.

A drug developer with 30-plus years joins Entera for a planned osteoporosis Phase 3 trial

Entera Bio (NASDAQ: ENTX) has appointed Riccardo Paolo Camisasca, M.D., as its new Chief Medical Officer, bringing over 30 years of global pharmaceutical R&D experience. This strategic hire strengthens Entera's clinical leadership as the company prepares for a planned Phase 3 trial for EB613, its oral osteoporosis treatment. EB613 previously demonstrated positive results in a Phase 2 study, meeting all biomarker and bone mineral density endpoints with a favorable safety profile.

Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement

Short Interest in Entera Bio Ltd. (NASDAQ:ENTX) Increases By 286.7%

Short interest in Entera Bio Ltd. (NASDAQ:ENTX) surged by 286.7% to 1.15 million shares as of July 31st, though its days-to-cover ratio remains low at 0.2 due to high trading volume. The company's stock opened lower at $2.80 after reporting a quarterly loss worse than analyst estimates. Despite institutional ownership of 14.11%, analysts have a mixed "Hold" rating with a $9.00 price target.

Entera Bio (ENTX) completes $275M Rule 506(b) private offering of shares and warrants

Entera Bio Ltd. announced the completion of a $275 million private offering under Regulation D Rule 506(b). The company successfully sold 122,961,215 ordinary shares and 11,842,695 pre-funded warrants, with no remaining securities to be sold. This offering, which commenced on July 28, 2026, significantly strengthens Entera Bio's capital base.

Entera Bio (NASDAQ:ENTX) Announces Earnings Results

Entera Bio (NASDAQ:ENTX) reported a quarterly loss of $0.14 per share, missing analyst expectations of a $0.08 loss. Despite this, ENTX shares rose slightly to $2.87. The company, a clinical-stage biopharmaceutical firm focusing on orally delivered peptide therapeutics, has a market capitalization of $141.5 million, with institutional investors owning 14.11% of the stock.

Entera Bio (ENTX) awards 180,000 options to Chief of R&D

Entera Bio Ltd. has granted its Chief of R&D, Gregory Burshtein, 180,000 stock options to purchase ordinary shares at an exercise price of $1.37 per share. These options, which expire on May 7, 2036, will vest over a three-year period starting May 7, 2026, with full acceleration upon a Change in Control. This transaction was reported via an SEC Form 4 filing, indicating an insider trade with a neutral impact and sentiment.

Entera Announces Second Quarter 2026 Financial Results and Business Updates

U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis Oversubscribed $275 Million Private Placement Led by BVF Partners L.P. (“BVF”) with Participation from Leading Institutional Healthcare Investors to Fund EB613 through Anticipated Submission of NDA to the FDA EB613 Phase 3 Study Initiation Planned for Late 2026 with Topline Data Anticipated in the Second Half of 2028 IND Enabling Studies Ongoing for EB612 - the First Oral Peptide Replacemen

Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1%

A Schedule 13G filing for Entera Bio Ltd. (ENTX) reveals that Longitude Venture Partners V, L.P. (LVPV) and related entities report a 4.6% ownership stake, comprising 7,843,138 ordinary shares. The filing also indicates that Seven Fleet may beneficially own 4.1% of the ordinary shares, totaling 7,053,898 shares, although group status and related beneficial ownership are disclaimed by the reporting persons. This disclosure provides transparency on significant ownership positions in Entera Bio.

Entera Bio (ENTX) sees BVF build 9.99% stake after $275M financing

Biotechnology Value Fund (BVF) and its affiliates have reported a 9.99% beneficial ownership stake in Entera Bio Ltd. (ENTX) following significant financing rounds in April and July 2026. These financings, including a $275 million private placement in July, led to BVF acquiring over 17 million ordinary shares and various warrants. The agreement also grants BVF the right to designate up to two directors to Entera Bio's board, contingent on maintaining specific ownership thresholds.